Why the absence of earnings guidance is a concern
Why the absence of earnings guidance is a concern
General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.
About this video
At the half way point of earnings season in US, Hugh Selby-Smith from Talaria Capital says most interesting is that many companies are withdrawing or not offering guidance. He says so far the market has more actively punished those offering bad guidance than those
withdrawing guidance. He also notes that the strong US dollar is impacting earnings, all of which adds up to a lack of certainty for the months ahead. Hugh says as it stands Fed tightening is not even done and the likely recession is still ahead of us, so it's still too early to be thinking about the next bull market. Hugh believes that is probably a conversation that starts late 2023 - 2024.
Drug maker Pfizer has raised its forecast for sales of as its third-quarter profit beat estimates, due to higher-than-expected sales of the vaccine. The result sent shares of rival vaccine makers Moderna higher. However, Eli Lilly shares fell as it forecast annual profit and revenue below estimates, as a contended with the strong US dollar.
As far as the outlook for global pharmaceutical stocks, Talaria's preference is Novartis, which High says has $4bn free cash flow, 9% return on capital and billions of dollars in R&D, some which will flow into future earnings.